Cart
sales@molnova.com
Seralutinib
CAS No. 1619931-27-9
Seralutinib( GB002 )
Catalog No. M23717 CAS No. 1619931-27-9
Seralutinib is an inhibitor of inhaled PDGFRα and PDGFRβ. It is used in the study for pulmonary arterial hypertension.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 93 | In Stock |
|
| 2MG | 56 | In Stock |
|
| 5MG | 93 | In Stock |
|
| 10MG | 140 | In Stock |
|
| 25MG | 250 | In Stock |
|
| 50MG | 323 | In Stock |
|
| 100MG | 514 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSeralutinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionSeralutinib is an inhibitor of inhaled PDGFRα and PDGFRβ. It is used in the study for pulmonary arterial hypertension.
-
DescriptionSeralutinib is an inhibitor of inhaled PDGFRα and PDGFRβ. It is used in the study for pulmonary arterial hypertension.
-
In Vitro——
-
In Vivo——
-
SynonymsGB002
-
PathwayAngiogenesis
-
TargetPDGFR
-
RecptorPDGFRα|PDGFRβ
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1619931-27-9
-
Formula Weight469.55
-
Molecular FormulaC27H27N5O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL?(212.98 mM;?Need ultrasonic)
-
SMILESCC1=CC(=CN=C1)C(=O)NC2=CC=CC(=C2)[C@H](C)NC3=NC(=CN=C3)C4=CC(=C(C=C4)OC)OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Anna Galkin, et al. Pharmacologic Characterization of GB002, a Novel Inhaled PDGFR Kinase Inhibitor in Development for Pulmonary Arterial Hypertension (PAH).
molnova catalog
related products
-
Bleomycin hydrochlor...
Bleomycin hydrochloride is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin hydrochloride is an antitumor antibiotic.
-
PP58
PP58 is an inhibit of PDGFR, FGFR and Src family.
-
Toceranib
Toceranib phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively), has antitumor and antiangiogenic activity.
